Dear Friends of TAG,

Thank you for your enduring support throughout the past year. This annual report provides a brief update from 2010 and provides you, our supporters, with our 2010 financial report.

Last year continued to be a challenging year for AIDS activism—politically and economically—but there were many promising developments. New studies showed that microbicides or oral antiretrovirals showed varying levels of protection from HIV for women and for men who have sex with men, respectively. These studies demonstrated that current treatments could be used prophylactically to at least partially prevent HIV infection—thus advancing the field of biomedical interventions for HIV prevention and adding two powerful new tools to the prevention arsenal. In other positive developments, a revolutionary TB diagnostic test called GeneXpert is much more accurate in the detection of TB and can diagnose active TB disease in a matter of hours versus weeks or months using current diagnostic procedures. This is quite literally a lifesaving development for many people who are coinfected with TB and HIV. Despite this exciting news, current pricing of this diagnostic tool will keep it out of reach for many in developing countries. In the hepatitis arena, trials using direct-acting antivirals have demonstrated that hepatitis C can be cured in more people, more quickly with new drugs that are likely to be available in 2011.

And yet, despite these positive developments, the political and economic environment continued to challenge international and domestic treatment access: AIDS drug assistance programs in the United States had thousands of people on waiting lists to access lifesaving antiretroviral drugs. The Global Fund to fight AIDS, TB and Malaria was funded below austerity levels, and the U.S. President’s Emergency Plan for AIDS Relief was essentially flat-funded for a second year. This means scale-up of HIV treatment in developing countries could lose ground in contrast to the successes that have been achieved over the past ten years. Nevertheless, throughout 2010, TAG fought to engage federal and global policy makers to ensure that HIV treatment access and scale-up stays on the health agenda and to let them know there is no justification to cut back at the cost of human lives.

As we move into 2011 and beyond, TAG will focus on activism that accelerates research to cure AIDS. We will undertake a targeted campaign to make this happen, with specific outcomes and goals over the next four years. If you are interested in this campaign, please visit www.treatmentactiongroup.org/cure.aspx.

TAG’s powerful team of nine committed treatment activists will continue in 2011 to lead advocacy and education efforts in HIV, hepatitis, and TB. Consulting with experts, researchers, and leading institutions, TAG will continue to shape the agenda in HIV treatment, prevention and the ultimate goal of a vaccine and a cure for HIV.

Your continued support and investment in TAG provides us with the resources that allow us to catalyze actions among policy makers, researchers, scientists, and activists.

Though 2010 brought many positive developments, our work is far from done.

Please consider increasing your gift to TAG this year so that we can continue to relentlessly advocate for new treatments, better prevention, and an end to the AIDS epidemic.

Barbara Hughes
President, Board of Directors
TAG’s 2010 Research in Action Awards in New York City honored individuals who have made significant contributions to AIDS research and activism.

This year’s honorees were Scott Campbell, executive director of the Elton John AIDS Foundation; Dr. Steven G. Deeks, professor of medicine at the University of California–San Francisco; Dr. Mehmet Oz, host of The Dr. Oz Show and New York Times best-selling author; and James Wentzy, New York City–based artist, director, and activist. For the second time, Jenna Wolfe from the Weekend Today show hosted the event and brought charm, intellect, and humor to an evening that was a fund-raising record-breaker. Dr. Deeks noted that he was “blown away” that TAG is only ten people strong, and Billie Jean King called TAG “small and mighty.” Dr. Oz noted, “a few dedicated folks can make a massive difference.”

With all the accolades for TAG from our presenters and honorees, Dr. Oz summed it up by reminding us all that “there is a lot more to do” in science and activism to end the AIDS epidemic.
TAG’s Work Toward a Cure

The pursuit of a cure for HIV/AIDS has always been a cornerstone of TAG’s mission. Over the past few years, encouraging evidence has emerged suggesting that this long-sought goal may be achievable. In particular, the case of an individual who appears to have been cured of HIV infection as a result of undergoing a complex set of treatments for cancer has helped reinvigorate the field by providing a proof-of-concept example that a cure is possible. TAG has been at the forefront of efforts to advance cure-related HIV research:

- In November 2008, TAG cosponsored a scientific workshop on cure research with Project Inform and amfAR. The workshop played an important role in making cure-related research one of the new priorities for NIH-funded HIV research networks and led to the establishment of the amfAR Research Consortium on HIV Eradication (ARCHE).
- In July 2010, TAG cosponsored an International AIDS Society (IAS) workshop, “Towards a Cure,” that took place directly ahead of the 2010 International AIDS Conference in Vienna. TAG’s support allowed ten community members to attend the workshop. TAG’s Basic Science, Vaccines, and Prevention Project coordinator Richard Jefferys coauthored a posting about the meeting for the 2010 International AIDS Conference website and wrote the meeting report, which was published in the Journal of the International AIDS Society. TAG’s executive director Mark Harrington was invited to join the steering committee for the new IAS cure research initiative.
- In April 2011, TAG cosponsored a workshop focused on issues in clinical research that need to be addressed in order to accelerate the discovery of a cure. Cosponsors were the AIDS Policy Project, amfAR, and Project Inform.

TAG’s Focus on Evolving Hepatitis C Treatment

Worldwide, more than five million people are coinfected with hepatitis C virus (HCV) and HIV. In the United States, at least 350,000 people are HIV/HCV coinfected. Liver disease from hepatitis C coinfection is a leading cause of death among people with HIV/AIDS—despite access to antiretroviral therapy. Yet hepatitis C can be cured in HIV-positive people.

TAG has focused on hepatitis C for over a decade. Now, there are dozens of new drugs in development, the first two are likely to be available in mid-2011, and the HCV treatment paradigm is shifting, hopefully toward the eventual goal of very effective, less toxic, short-course treatment with a combination of oral antiviral drugs. TAG’s Hepatitis/HIV Project draws from the core values, history, and successes of HIV activism to inform its broad strategy, encompassing hepatitis C drug development, basic and clinical research, policy, and access. This strategy is paying off: more people will be cured in the coming years than ever before.

In early 2010, TAG’s Hepatitis/HIV Project director, Tracy Swan, launched the Hepatitis C Community Advisory Board (H-CAB), allowing treatment activists from the hepatitis and HIV communities to advocate for early access to lifesaving drugs, and for well-designed, clinically relevant trials. H-CAB has established itself as a powerful and credible force, advocating for patients with regulators, medical providers, and pharmaceutical companies.

TAG’s Hepatitis/HIV Project works with allies to broaden access to hepatitis C treatment, both domestically and globally. Tracy Swan participated in a landmark session on hepatitis C treatment access at the XVIII 2010 International AIDS Conference in Vienna, Austria, coorganized a multi-stakeholder meeting on HCV drug development for HIV/HCV coinfected people with the European AIDS Treatment Group, and continued to work closely with colleagues in Thailand and Eastern Europe. She is a member of the U.S.-based Hepatitis Fair Pricing Coalition, a group working to lower drug prices in the United States.

TAG’s Hepatitis/HIV Project initiated a campaign to urge the government to create an expert, standing, multidisciplinary hepatitis C treatment guidelines panel. This panel has the opportunity to ensure that payers cover the standard of care as it evolves, and that advances in HCV drug development translate into cures for people.
TAG Limited Edition
2010

fierce pussy, Twisted, 2010, individually redacted, white out on photocopy + wood frame

Every year at its annual Research in Action Awards ceremony, TAG presents a new limited-edition artwork, generously donated by a highly regarded visual artist.

Contributing artists have included Donald Moffett, Tony Feher, Carrie Yamaoka, and David Armstrong.

fierce pussy is a collective of queer women dedicated to creating public art and direct action addressing issues of lesbian identity and visibility. Emerging in 1991 through its members’ immersion in AIDS activism during a decade of increasing political mobilization around gay rights, fierce pussy brought lesbian identity directly into the streets. Calibrating the visual language of their art to the urgency of those years, the collective’s art production relied on modest and readily available resources: old typewriters, found photographs, its members’ own baby pictures, and the printing supplies and equipment accessible in their day jobs. Lo-tech, low budget, and ubiquitous, fierce pussy’s wheatpasted posters and crack-and-peel stickers peppered New York City through the early 1990s. In other actions, the collective used stencils and spray paint to rename New York City streets after prominent lesbian heroines, and engaged in an iconoclastic greeting card campaign directed at Cardinal O’Connor and Senator D’Amato.

Most active between 1991 and 1995, fierce pussy has reconvened in recent years to create new works that reframe the collective’s vital message for the present moment.

For artworks offered at past Research in Action Award ceremonies visit our website at http://www.treatmentactiongroup.org/base.aspx?id=210 or contact TAG at 212.253.7922.

TAG PROGRAM AREAS

Treatment Action Group’s activist priorities include HIV, basic science, vaccines, prevention, hepatitis, and tuberculosis.

HIV
TAG’s HIV Project works with the HIV community, scientists, government institutions, and the pharmaceutical industry to speed the delivery of safer, more tolerable, and more effective drugs to people with HIV across the globe, and to promote research to find a cure for HIV/AIDS. In addition, TAG tracks and analyzes the economic and political landscape that impact treatment scale-up and treatment access.

Basic Science, Vaccines, and Prevention
TAG’s Basic Science, Vaccines, and Prevention Project works with HIV community members, scientists, and policy makers to enhance public understanding of the science of HIV infection, HIV pathogenesis and to address gaps in HIV research, critique the research efforts, and foster cross-disciplinary collaborations. The basic science program works to accelerate research into HIV pathogenesis and to speed the development of effective immune-based therapies, preventive technologies, a vaccine and a cure.

Viral Hepatitis and HIV
TAG’s Hepatitis/HIV Project works with the hepatitis C and HIV community, scientists, government, and drug companies to make lifesaving information along with safer, more tolerable, and more effective hepatitis C treatment available to all people who need it. In 2011, new treatments for hepatitis C virus (HCV) are changing the standard of care and TAG is providing leading-edge community information and educational materials targeted to people infected or affected by HCV.

Tuberculosis and HIV
People at risk for both diseases require tuberculosis and HIV services that work together to address their needs. The Treatment Action Group’s TB/HIV Project is working to accelerate progress in program scale-up and research and development to eliminate TB as a global public health threat.


$100,000 OR MORE
The Bill & Melinda Gates Foundation
The Michael Palm Foundation

$50,000—$99,999
Elton John AIDS Foundation
The Christy & John Mack Foundation
World Health Organization/Stop TB Partnership

$25,000—$49,999
Genentech Inc./Roche Group
Gilead Sciences, Inc.
Levi Strauss Foundation
Newman’s Own Foundation

$10,000—$24,999
amfAR, the Foundation for AIDS Research
Bickerstaff Family Foundation
Bristol-Myers Squibb
Broadway Cares/Equity Fights AIDS
City of New York/New York City Council
Gesso Foundation
JVT/Diamond Information Center
Merck & Co.
James Saakvitne & Daniel Chow
Tibotec Therapeutics
World Health Organization/UNAIDS

$5,000—$9,999
AIDS Global Action
A|X Armani Exchange
Katherine C. & Thomas M. Ash III "In Memory of Anne Cooney"
Barclays Capital
Centers for Disease Control and Prevention
Kenneth Cole Foundation
Columbia University, Division of Cardiothoracic Surgery
David Corkery
Richard A. & Barbara Knowles Debs/The Debs Foundation
Dr. Michael F. Giordano
Global Health Strategies
Tim Iversion, Andrew Xu & Nunu Xu
Sir Elton John & David Furnish
Stephen Mack & Robert Monteleone
Raffy & Jo Manoukian
Open Society Foundations

$2,500—$4,999
Boehringer Ingelheim Pharmaceuticals
M. Lee Garrison
Steven & Judith Gluckstern "In Memory of Michael Palm"
Kevin Goetz/Screen Engine LLC
Richard M. Lynn & Joseph Evall
Alby P. Maccarone, Jr.
Robert J. McLain
Linda M. & Stuart K. Nelson
Rabin Strategic Partners
Roesch Family Fund
Steven J. Sharif
Andrew David Zacks Foundation

$1,000—$2,499
AIDS Vaccine Advocacy Coalition/Mitchell Warren
Barneys New York
David Bohnett Foundation
Scott P. Campbell
Don Capoccia & Tom Pegasus
Timothy & Mary Casey
Craig Cichy
Donald DeLine
The Irene Diamond Fund
Randall G. Drain
HHH Princess Fiyal of Jordan
David France & Joy Tomchin
William Gilbane III
David Gold
Judith & Richard Harrington
Mark Harrington
Dr. William A. Haseltine
Florette B. Hoffheimer

Barbara F. Hughes & Andrea Benzacar Dailey
Kaiser Family Foundation
Noel E.D. Kirnmon & Michael D. Paley
LWP/Livideni Weifened Partners
The Dorothy Loudon Foundation/Lionel Larner
Madison Square Garden/f u s e
Terence S. McDaniel & Emily Souvaine Meehan
Albert S. Messina & Ken Jennings
Kenneth T. Monteiro & Leo J. Blackman
Mark O’Donnell & James E. McGeever
Joshay O’Connor & Richard Schubel
People Magazine/Martha Nelson
Evelyn M.M. & John G. Popp
Michael L. Rankowitz & Sheila A. Heffron
Walter Rieman “In Memory of Tom Stoddard”
Howard Rose Agency “In Honor of Scott Campbell”
Dr. Bruce R. Schackman & Edward K. Sikov
Evan Schwartz & Robert Fitterman
Ellen & Gerald Sigal
Dr. Peter Small & Dr. Delaney Ruston
Monte Steinman
Jon Stryer/Arcus Fund
Donn Vecchie-Campbell
W. Kirk Wallace & Mark M. Sexton Fund of Stirling Community Foundations
Irwin J.P. Warren
Alfred J. Yieries

$500—$999
Benjamin, Christine & Darius Anagnos
Jeffrey Arnstein & Michael Field
Steve Asher
Johnny & Eddi Barbis
Alvin H. Baum, Jr.
Carl Berg PhD & Judith Green PhD
Jeanne L. Bergman & Anna Kramarsky
Andrew Boose & Bennah Serfaty
Elia & Jullie Camhi
Dr. & Mrs. Charles C.J. Carpenter
Paula Chaflin & Megan Chaflin
City National Bank
Concerned Parents for AIDS Research
Arienne Z. Dar
Edward J. Davis & Thomas D. Phillips
Jeff Davis & Kevin Jennings
Dinowitz & Bove
Simon Doonan
Hon Thomas K. Duane & Louis Webley
Joy Episalla & Carrie Yamaoka
John L. Gil & Associates
Brad Goldfarb & Alfredo Paredes
Great Jones Realty
Dr. Walt R. Hadikin & Kevin Hughes
Charles E. Hamlens
The Hargrove Pierce Foundation “In Honor of Mike Nichols”
Fred Hersch & Scott W. Morgan
Housing Works/Charles King & Andrew Greene
Lee Jones
Paul E. Kennedy
Mathilde Krim, PhD
Anne Hodge Livet
Michael Longacre
Jenna A. Mack
Hermes Mallea & Carey Maloney
Joe McMillan
Anthony & Celeste Meier
Andrew Morrison “In Honor of Xorin Balbes”
George & Mirla Morrison
Robert Munk
Partners in Health
Pamela Perkins
Laurie Peter & Betsy Bernard
Lisa Peterson
Mark Pogachefsky
Dr. Elizabeth S. Powell & Steven M. Frank
Michael H. Rauch
Harriet T. Rosenberg
Paul Sack
David Sigal & Brad Hoylman
Rob Southern

$250—$499
Leslie Asako-Gladsjo & Blake C. Leyh
Lydia M. Ashcroft “In Honor of Barbara Hughes”
Dr. Judith D. Auerbach
The Paul Bierne Foundation “In Honor of Terrence McNally & Scott Campbell”
Gregory Belzberg
Dr. Kenneth Berger
William Berger
Marc J. Berman & John Yakubik
Constance H. Boykan
Prof. Richard M. Buxbaum & Catherine B. Hartsnohn
Steven & Denise Chickery
Suzanne J. Cole
Louis Keith Corso “In Honor of Jason Osher”
Mrs. Denise B. Dailey
Erika Dailey
Scott Dainton
Joshua C. David & Stephen D. Hirsh “In Honor of TAG Board Member Robert Monteleone”
Lynda M. Dee
Dr. Stephen M. Dillon
Peter Morris Dixon
Douglas O. Drake
Marina Ein
Alan E. Farley
Kandy Ferrere & Laine Nauman “In Honor of Scott Campbell”
Carol & John Field Fund of Fidelity Charitable Gift Fund
Sabina Fila
Donna Futterman, MD
Margaret Garber-Steinberg
Ron Goldberg & Joe Chiplock
Ken Goody “In Honor of Scott Campbell”
Karen R. & Werner L. Gundersheimer
Craig T. Hempstead & John Ricotta
Patrick Jordan
John Kander
Daniel Karchem
Keviin Kish
Cindy Kleine
Jeffrey A. Laurence, MD
James LaVigne
Winston B. Layne
Robert Levin & Hilda Wynn
Joseph McConnell & Erik Haagensen
Constance McKey
Bill Metzger
Laurie Morrison
Patrick Niccola
Donna M. Pauldine “In Memory of Jeff Palladino”
Philip Pierce
Leslie Fay Pomerantz
Andrew & Andrea Potash
Daphne E. Powell & Christopher Harrington
Linda Reid & Kathrynn Clubb
Jorge Rodriguez
Daniel C. Scheffey
Sue Sera/Sena Consulting
Keith S. Tobin, MD
Mimma & Lorenzo Viglezio
Mark Wyn “In Memory of Gordon Brown”
Anthony Zisa

In-Kind Donations
A|X Armani Exchange
David Barton Gym
Harney & Sons fine teas
it’s the watsons
J. Lohr Vineyards & Wines
Jive Label Group/SONY BMG Entertainment
Keith Haring Foundation
LARBAR
POZ Magazine
Sephora
The Dumpling Diva
TAG FINANCIALS 2010

STATEMENTS OF FINANCIAL POSITION

Assets

**Current assets:**
- Cash and cash equivalents: $1,107,256, $1,425,566
- Contributions receivable: 1,078,031, 1,040,096
- Prepaid expenses and other receivables: 7,517, 10,718

**Total Current Assets:** $2,192,804, $2,476,380

- Property and equipment—net of accumulated depreciation: 35,369, 51,283
- Security deposits: 20,654, 20,654

**Total Assets:** $2,248,827, $2,548,317

Liabilities and Net Assets

**Current liabilities:**
- Accounts payable and accrued expenses: $2,860, $16,142

**Total Liabilities:** $2,860, $16,142

**Net assets:**
- Unrestricted: 1,068,959, 1,270,302
- Temporarily restricted: 1,177,008, 1,261,873

**Total Net Assets:** $2,245,967, $2,532,175

**Total Liabilities and Net Assets:** $2,248,827, $2,548,317

Statement of Cash Flows

**Cash flows from operating activities:**
- Decrease in net assets: $(286,208), $(162,206)
- Adjustments to reconcile increase in net assets to net cash provided by operating activities:
  - Depreciation: 17,264, 16,099
- (Increase) Decrease in current assets:
  - Contributions receivable: (37,935), 213,001
  - Prepaid expenses and other receivables: 3,201, 4,256
  - Security deposits: - , -
- (Decrease) increase in current liabilities:
  - Accounts payable and accrued expenses: (13,282), 13,512

**Net cash (used in) provided by operating activities:** $316,960, $84,662

**Cash flows from investing activities:**
- Purchases of property and equipment: (1,350), (9,421)
- Net cash used in investing activities: (1,350), (9,421)
- Net (decrease) increase in cash balance: (318,310), 75,241

**Cash, beginning of year:** 1,425,566, 1,350,325

**Cash, end of year:** $1,107,256, $1,425,566
TAG FINANCIALS 2010

STATEMENTS OF ACTIVITIES

Revenue and support:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Year ended December 31</td>
<td>2010</td>
</tr>
<tr>
<td>Direct mail</td>
<td>$ 40,808</td>
<td>$ 40,808</td>
</tr>
<tr>
<td>Donations</td>
<td>$ 20,331</td>
<td>$ 20,331</td>
</tr>
<tr>
<td>Grants</td>
<td>$ 278,343</td>
<td>$ 1,177,008</td>
</tr>
<tr>
<td>Special-event income</td>
<td>$ 401,650</td>
<td>$ 401,650</td>
</tr>
<tr>
<td>Travel and other reimbursement</td>
<td>$ 45,466</td>
<td>$ 45,466</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>$ 5,136</td>
<td>$ 5,136</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>$ 1,261,873</td>
<td>$ 1,261,873</td>
</tr>
<tr>
<td>TOTAL REVENUE AND SUPPORT</td>
<td>$ 791,734</td>
<td>$ 1,177,008</td>
</tr>
</tbody>
</table>

Expenses:

Program Services
- Antiretroviral Project: $53,277, $53,277, $77,780
- Michael Palm HIV Pathogenesis and Prevention Project: $202,342, $202,342, $224,907
- Hepatitis/HIV Project: $236,979, $236,979, $300,233
- TB/HIV Advocacy Project: $1,484,152, $1,484,152, $1,241,677
- U.S and Global Health Policy Project: $12,927, $12,927, $47,530
- Communications: $12,983, $12,983, $14,134

TOTAL PROGRAM EXPENSES: $2,002,660, $2,002,660, $1,906,261

Management and general: $116,977, $116,977, $131,481
Fundraising: $135,313, $135,313, $92,696

TOTAL SERVICES EXPENSES: $2,254,950, $2,254,950, $2,130,438

Decrease in net assets: $(201,343), $(84,865), $(286,208), $(162,206)
Net assets, beginning of year: $1,270,302, $1,261,873, $2,532,175, $2,694,381

NET ASSETS, END OF YEAR: $1,068,959, $1,177,008, $2,245,967, $2,532,175

SUMMARY OF 2010 FUNCTIONAL EXPENSES

- Program Services: 88.81%
- Management & Administration: 5.19%
- Fundraising: 6.00%
The 2010 Palm Donor Circle
Special Recognition by TAG

The Palm Donor Circle of the Treatment Action Group is TAG’s major donor program, named in honor of philanthropist and TAG supporter Michael Palm (1951–1998). Members of the Palm Donor Circle made individual donations of $1,000 or more to TAG in 2010.

Katherine C. & Thomas M. Ash III
Glen & Debbie Bickerstaff
David Bohnett
Scott P. Campbell
Don Capoccia & Tom Pegues
Timothy & Mary Casey
Craig Cichy
Kenneth & Maria Cuomo Cole
David Corkery
Richard A. & Barbara Knowles Debs
Donald DeLine
Randall G. Drain
HRH Princess Firyal of Jordan
David France & Joy Tomchin
M. Lee Garrison
William Gilbane III
Dr. Michael F. Giordano
Steven & Judith Gluckstern
Kevin Goetz
David Gold
Judith & Richard Harrington
Mark Harrington
Dr. William A. Haseltine
Florette B. Hoffheimer
Barbara F. Hughes & Andrea Benzacar Dailey
Tim Iverson, Andrew Xu & Nunu Xu
Sir Elton John & David Furnish
Noel E.D. Kirnon & Michael D. Paley

Richard M. Lynn & Joseph Evall
Alby P. Maccarone, Jr.
Christy & John Mack
Stephen Mack & Robert Monteleone
Raffy & Jo Manoukian
Robert J. McLain
Terence S. & Emily Souvaine Meehan
Albert S. Messina & Ken Jennings
Kenneth T. Monteiro & Leo J. Blackman
Linda M. & Stuart K. Nelson
Mark O’Donnell & James E. McGreevey
Jason Osher & Richard Schubel
Evelyn M.M. & John G. Popp
Michael L. Rankowitz & Sheila A. Heffron
Walter Rieman
Scott & Pondra Roesch
James Saalvitz & Daniel Chow
Dr. Bruce R. Schackman & Edward K. Sikov
Evan Schwartz & Robert Fitterman
Steven J. Sharif
Ellen & Gerald Sigal
Dr. Peter Small & Dr. Delaney Ruston
Monte Steinman
Jon Stryker
Donn Vecchie-Campbell
W. Kirk Wallace & Mark M. Sexton
Irwin J.P. Warren
Alfred J. Yeries
Andrew David Zacks

TAG BE INVOLVED

About TAG
Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.

Program areas include AIDS policy issues, antiretroviral treatment, basic science, vaccines, viral hepatitis, and tuberculosis.

Join TAG’s Board
TAG is always seeking new board members. If you are looking for a great place to invest your time and talents, please call Barbara Hughes, TAG board president, to learn more about board opportunities with TAG.

212.253.7922
barbara.hughes@treatmentactiongroup.org

Contribute!
TAG welcomes donations from individuals who want to see the AIDS research agenda remain responsive to the needs of all people living with HIV.

To make a charitable donation to TAG, call 212.253.7922 or go online to www.treatmentactiongroup.org.